Taking Part in Research
Taking Part in Research at Seattle Children's
Your child’s health and well-being are of utmost importance to us, just as we know they are to you. So as you think about whether to take part in research, consider these factors.
Safety is a top priority
Before a study ever opens to participants, it goes through many layers of review to help protect their safety. Oversight continues during the study. For example, the National Cancer Institute (NCI) monitors many of the studies we offer. If participants from another hospital in the study have side effects from the study treatment, NCI reports this information to us. We also have an ethics board within Children’s that reviews studies for participants’ protection. This is called an institutional review board, or IRB. You will get information about the risks of a study before you decide to join.
Your information is kept confidential
Taking part in research does not end your right or your child’s right to have healthcare information kept private. When researchers share or publish information about a study, they do not include details that would reveal your identity or your child’s identity to anyone else unless you give permission to do so.
Your child may get the same treatment as usual
In a phase III trial, each participant gets either an experimental therapy or standard treatment. Neither you nor the research team will decide which your child gets; your child will be randomly assigned to one group or the other by a computer program. Researchers do this type of study when they have reason to think the experimental therapy may be at least as safe and effective as the standard. But there is no guarantee — they are doing the study in order to find out.
Study Outcomes for ALL (Acute Lymphoblastic Leukemia)
In this video, Blythe Thomson, MD, pediatric oncologist, discusses findings from a Seattle Children's study that looked at outcomes for youth who participated in a clinical trial for ALL (acute lymphoblastic leukemia), compared with those who did not participate in trials. For more information, please read the associated press release.